MARKET

ESPR

ESPR

Esperion Therape
NASDAQ
0.7982
-0.0946
-10.60%
After Hours: 0.8099 +0.0117 +1.47% 19:59 05/09 EDT
OPEN
0.9051
PREV CLOSE
0.8928
HIGH
0.9310
LOW
0.7301
VOLUME
11.79M
TURNOVER
--
52 WEEK HIGH
3.940
52 WEEK LOW
0.7301
MARKET CAP
158.20M
P/E (TTM)
-1.0043
1D
5D
1M
3M
1Y
5Y
1D
Esperion and HLS partner to commercialize heart disease treatments in Canada
Seeking Alpha · 3d ago
Esperion’s Strategic Expansion and Promising Financial Outlook Earns Buy Rating
TipRanks · 3d ago
Esperion enters license and distribution agreement with HLS Therapeutics
TipRanks · 3d ago
*Esperion Therapeutics 1Q Loss/Shr 14c >ESPR
Dow Jones · 3d ago
*Esperion Therapeutics 1Q Rev $12.6M >ESPR
Dow Jones · 3d ago
HLS Therapeutics Agrees With Esperion Therapeutics To In-License And Commercialize NEXLETOL And NEXLIZET In Canada
Benzinga · 3d ago
HLS THERAPEUTICS: 2025 FINANCIAL TARGETS ARE UNCHANGED
Reuters · 3d ago
HLS THERAPEUTICS: Q1 NET LOSS $0.14 PER SHARE
Reuters · 3d ago
More
About ESPR
More
Esperion Therapeutics, Inc. is a commercial stage biopharmaceutical company. The Company is focused on developing and commercializing oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (CVD) and are struggling with elevated low-density lipoprotein cholesterol (LDL-C). Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. Its NEXLETOL and NEXLIZET (bempedoic acid and ezetimibe) tablets are oral, once-daily, non-statin medicines to lower the risk of myocardial infarction and coronary revascularization in adults with primary hyperlipidemia. Its NEXLETOL is an ATP Citrate Lyase (ACLY), inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors. Its NUSTENDI contains bempedoic acid and ezetimibe and lowers elevated LDL-C through complementary mechanisms of action by inhibiting cholesterol synthesis in the liver and absorption in the intestine.
Recently
Symbol
Price
%Change

Webull offers Esperion Therapeutics Inc stock information, including NASDAQ: ESPR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ESPR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ESPR stock methods without spending real money on the virtual paper trading platform.